Siemens Healthineers Forecasts 4%-5% Revenue Growth
The medical technology company issued its fiscal 2027 outlook after fourth-quarter results showed weakness in China diagnostics.
Updated on Nov. 5, 2026 in Healthcare
Siemens Healthineers issued its fiscal 2027 outlook projecting 4%-5% comparable revenue growth and adjusted basic earnings per share of 2.20 euros to 2.40 euros. The forecast followed fourth-quarter results in which revenue rose 7.3% while adjusted EBIT fell 2.0%.
Why it matters
Weakness in China continued to weigh on the diagnostics business, and China is the company's second-largest market after the US. The outlook comes as Siemens Healthineers prepares a planned spin-off from Siemens that shareholders are due to vote on in February 2027.
Fourth-quarter revenue rose 7.3% to 6.784 billion euros while adjusted EBIT fell 2.0% to 1.077 billion euros. Diagnostics revenue fell 4.2% on a comparable basis to 1.067 billion euros, and the company did not detail how much of that decline came from China.
The players
Siemens Healthineers
A German medical technology company that makes diagnostic and imaging equipment and is majority-owned by Siemens AG.
Siemens AG
The German industrial conglomerate whose planned spin-off of Siemens Healthineers is subject to a shareholder vote in February 2027.
The details
Siemens Healthineers reported fourth-quarter results on Thursday and paired them with a fiscal 2027 outlook. Diagnostics revenue in China was hurt by structural changes in the market environment, while the company also plans to change its name to Healthineers as part of the spin-off from Siemens.
Timeline
November 5, 2026: Fiscal 2027 outlook issued after fourth-quarter results.
February 2027: Shareholders are due to vote on the planned spin-off from Siemens.
Market Landscape
The outlook arrives as Siemens Healthineers prepares to separate from Siemens AG, a move that would make it an independent company under the name Healthineers. Its China diagnostics weakness highlights its exposure to the second-largest of its markets at a time when investors will be weighing the standalone business.
The outlook of 4%-5% revenue growth and 2.20 to 2.40 euros in adjusted earnings per share gives investors a concrete benchmark for fiscal 2027. Patients and hospitals relying on diagnostic equipment may see continued effects from the weaker China market as the company manages that segment.
The takeaway
Siemens Healthineers' outlook shows that its growth now depends on how it manages diagnostics in China while it prepares to stand on its own. Investors tracking the company should watch both the February 2027 shareholder vote and whether China diagnostics stabilizes in the coming quarters.
What happens next
Shareholders are due to vote on the planned spin-off from Siemens in February 2027, which will determine whether the company begins trading as Healthineers.
Further reading
For more on how medical technology firms are navigating global markets, explore our Healthcare coverage.
